NEW YORK – Tango Therapeutics on Monday began treating patients with MTAP-deleted solid tumors with its PRMT5 inhibitor TNG462 in a Phase I/II trial.
Researchers will enroll 159 patients in the trial. In the Phase I portion of the study, they will determine the maximum tolerated dose and the dosing schedule for TNG462. The Phase II dose-expansion portion will include patients with certain types of MTAP-deleted tumors including mesothelioma, cholangiocarcinoma, and malignant peripheral nerve sheath tumors. Patients will be screened for MTAP deletions using next-generation sequencing or immunohistochemistry.
In a statement, Tango CEO Barbara Weber estimated that MTAP deletions occur in 10 percent to 15 percent of solid tumors and noted there are currently no US Food and Drug Administration-approved treatments for this subset of patients.
Boston-based Tango's pipeline includes another PRMT5 inhibitor, TNG908¸ and TNG260, which inhibits the corepressor of repressor element-1 silencing transcription, or CoREST, complex. TNG908 is undergoing a Phase I/II trial involving patients with MTAP-deleted malignant peripheral nerve sheath tumors, non-small cell lung cancers, mesothelioma, and cholangiocarcinoma. The firm is studying TNG260 in combination with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in STK11-mutated tumors. The firm also has an agent in preclinical development in BRCA1/2-mutant tumors and other undisclosed candidates.